Idelalisib (CAL-101, GS-1101)

For research use only. Not for use in humans.

目录号：S2226 中文名称：艾代拉里斯，艾代拉利司

Idelalisib (CAL-101, GS-1101) Chemical Structure

CAS No. 870281-82-6

Idelalisib (CAL-101, GS-1101) 是选择性p110δ抑制剂，在无细胞试验中IC50为 2.5 nM；对 p110δ 表现出的选择性是对 p110α/β/γ 的 40 到 300 倍，对p110δ的选择性是对 C2β，hVPS34，DNA-PK 和 mTOR的400到4000倍。Idelalisib 还可诱导自噬。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1279.19	现货
10mg	RMB 972.85	现货
50mg	RMB 3867.24	现货
200mg	RMB 10401.3	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Idelalisib (CAL-101, GS-1101)发表文献192篇：

Cell, 2020, S0092-8674(20)31394-5

PubMed: 33147445 ( click the link to review the publication )

Nat Mater, 2019, 18(8):892-904

PubMed: 31235902 ( click the link to review the publication )

Lancet Oncol, 2018, 19(4):486-496

PubMed: 29475723 ( click the link to review the publication )

Cell, 2018, 173(2):470-484

PubMed: 29551267 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):982-995

PubMed: 30503705 ( click the link to review the publication )

Nature, 2017, 8;546(7657):302-306.

PubMed: 28562582 ( click the link to review the publication )

Nature, 2017, 23;542(7642):489-493.

PubMed: 28199309 ( click the link to review the publication )

Nature, 2017, 552(7683):121-125

PubMed: 29143824 ( click the link to review the publication )

Nature, 2016, 539(7629):437-442

PubMed: 27642729 ( click the link to review the publication )

Nature, 2015, 22;517(7535):460-5.

PubMed: 25517094 ( click the link to review the publication )

Nature, 2015, 517(7535):460-5

PubMed: ( click the link to review the publication )

Cancer Discov, 2014, 4(9):1022-35

PubMed: 25082755 ( click the link to review the publication )

Nature, 2013, 25;496(7446):523-7.

PubMed: 23619696 ( click the link to review the publication )

Mol Cell, 2021, 81(4):708-723.e5

PubMed: 33606974 ( click the link to review the publication )

J Exp Med, 2021, 218(2)e20200517

PubMed: 33075129 ( click the link to review the publication )

Cell Biol Int, 2021, 10.1002/cbin.11557

PubMed: 33501756 ( click the link to review the publication )

J Clin Invest, 2020, 19 pii: 134424

PubMed: 32191635 ( click the link to review the publication )

Nucleic Acids Res, 2020, 26;gkaa431

PubMed: 32453417 ( click the link to review the publication )

Mol-Ther, 2020, 6;28-5-:1263-1275

PubMed: 32145202 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1183-x

PubMed: 32034308 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):228

PubMed: 33115525 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2725

PubMed: 32977449 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-01117-8

PubMed: 33082556 ( click the link to review the publication )

Br J Cancer, 2020, 18

PubMed: 32418995 ( click the link to review the publication )
Front Immunol, 2020, 11:610523

PubMed: 33552071 ( click the link to review the publication )

Mol Cancer Ther, 2020, molcanther.0973.2019

PubMed: 33037136 ( click the link to review the publication )

Br J Haematol, 2020, 10.1111/bjh.17139

PubMed: 33216963 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 8

PubMed: 32382996 ( click the link to review the publication )

J Gerontol A Biol Sci Med Sci, 2020, glaa216

PubMed: 32877922 ( click the link to review the publication )

Mol Cancer Res, 2020, 11

PubMed: 32161139 ( click the link to review the publication )

J Cell Sci, 2020, 11 pii: jcs

PubMed: 32393599 ( click the link to review the publication )

Eur J Immunol, 2020, 8

PubMed: 32383488 ( click the link to review the publication )

Cancer Immunol Immunother, 2020, 69(4):501-512

PubMed: 31950225 ( click the link to review the publication )

Sci Rep, 2020, 1;10(1):8867

PubMed: 32483262 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Int J Biochem Cell Biol, 2020, 122:105734

PubMed: 32119989 ( click the link to review the publication )

Cell Biol Int, 2020, 10.1002/cbin.11322

PubMed: 32068318 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Turk J Haematol, 2020, 37(3):167-176

PubMed: 32160736 ( click the link to review the publication )

Iran J Pharm Res, 2020, 19(1):153-165

PubMed: 32922477 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:390

PubMed: 32817744 ( click the link to review the publication )

Blood Adv, 2020, 4(24):6106-6116

PubMed: 33351104 ( click the link to review the publication )

Blood Adv, 2020, 4(13):3072-3084

PubMed: 32634240 ( click the link to review the publication )

Data Brief, 2020, 32:106185

PubMed: 32904194 ( click the link to review the publication )

Viruses, 2020, 12(6):E652

PubMed: 32560319 ( click the link to review the publication )

Haematologica, 2020, 10.3324/haematol.2019.227215

PubMed: 31919082 ( click the link to review the publication )

Blood Adv, 2020, 4(18):4382-4392

PubMed: 32926124 ( click the link to review the publication )
Arterioscler Thromb Vasc Biol, 2020, 40(1):86-102

PubMed: 31597445 ( click the link to review the publication )

Gastroenterology, 2019, 157(6):1615-1629

PubMed: 31446059 ( click the link to review the publication )

Blood, 2019, 134(21):1821-1831

PubMed: 31527074 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0486-9

PubMed: 31148590 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0569-7

PubMed: 31471562 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2202

PubMed: 31831562 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2019.216218

PubMed: 31471373 ( click the link to review the publication )

Int J Cancer, 2019, 145(5):1312-1324

PubMed: 30737788 ( click the link to review the publication )

Am J Transplant, 2019, 19(5):1305-1314

PubMed: 30549430 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31601046 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):20

PubMed: 30709367 ( click the link to review the publication )

Cell Death Dis, 2019,

PubMed: 31801949 ( click the link to review the publication )

Cell Biol Toxicol, 2019, 10.1007/s10565-019-09487-3

PubMed: 31522336 ( click the link to review the publication )

Epigenetics, 2019, 1-16

PubMed: 31216925 ( click the link to review the publication )

Cancer Sci, 2019, 110(3):997-1011

PubMed: 30618098 ( click the link to review the publication )

J Immunol, 2019, 202(5):1397-1405

PubMed: 30692213 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(2):920-933

PubMed: 30394679 ( click the link to review the publication )

Lab Invest, 2019, 99(5):648-658

PubMed: 30679758 ( click the link to review the publication )

Front Microbiol, 2019,

PubMed: 32038504 ( click the link to review the publication )

Mar Drugs, 2019, 17(9)E526

PubMed: 31505769 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 381:114729

PubMed: 31445927 ( click the link to review the publication )

J Cell Biochem, 2019, 120(8):14004-14016

PubMed: 30957273 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 116:105615

PubMed: 31539632 ( click the link to review the publication )

Eur J Pharmacol, 2019, 842:89-98

PubMed: 30401630 ( click the link to review the publication )
Arch Pharm Res, 2019, 10.1007/s12272-019-01163-8

PubMed: 31161369 ( click the link to review the publication )

Iran J Pharm Res, 2019, 18(Suppl1):119-131

PubMed: 32802093 ( click the link to review the publication )

Blood Adv, 2019, 3(20):2920-2933

PubMed: 31648314 ( click the link to review the publication )

EMBO J, 2018, 37(11)

PubMed: 29669863 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(1):120-129

PubMed: 29066507 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(5):1103-1113

PubMed: 29246942 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3967-3980

PubMed: 29666304 ( click the link to review the publication )

Cancer Immunol Res, 2018, 6(10):1150-1160

PubMed: 30089638 ( click the link to review the publication )

Cell Rep, 2018, 22(4):860-868

PubMed: 29420173 ( click the link to review the publication )

Cell Rep, 2018, 24(8):2155-2166

PubMed: 30134175 ( click the link to review the publication )

EBioMedicine, 2018, 31:217-225

PubMed: 29759484 ( click the link to review the publication )

Cell Death Dis, 2018, 9(12):1160

PubMed: 30478302 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):935

PubMed: 30224718 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2091-2099

PubMed: 30045927 ( click the link to review the publication )

Br J Haematol, 2018, 182(5):654-669

PubMed: 29978459 ( click the link to review the publication )

Br J Haematol, 2018, 183(3):428-444

PubMed: 30125933 ( click the link to review the publication )

J Immunol, 2018, 201(2):406-416

PubMed: 29884706 ( click the link to review the publication )

J Cell Physiol, 2018, 233(8):6052-6066

PubMed: 29319168 ( click the link to review the publication )

Eur J Immunol, 2018, 48(11):1796-1809

PubMed: 30184252 ( click the link to review the publication )

Ann Hematol, 2018, 97(5):839-849

PubMed: 29359239 ( click the link to review the publication )

Eur J Haematol, 2018, 10.1111/ejh.13075

PubMed: 29617050 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29423101 ( click the link to review the publication )

JCI Insight, 2018, 3(11)

PubMed: 29875321 ( click the link to review the publication )

Oncotarget, 2018, 9(30):21166-21181

PubMed: 29765528 ( click the link to review the publication )
Oncotarget, 2018, 9(31):21820-21830

PubMed: 29774105 ( click the link to review the publication )

Oncotarget, 2018, 9(10):9273-9284

PubMed: 29507689 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29565-29573

PubMed: 30038704 ( click the link to review the publication )

Oncotarget, 2018, 9(40):26019-26031

PubMed: 29899839 ( click the link to review the publication )

Blood, 2017, 5;129(1):88-99

PubMed: 27784673 ( click the link to review the publication )

Blood, 2017, 27;130(4):501-513

PubMed: 28533307 ( click the link to review the publication )

Blood, 2017, 1;129(22):3000-3008

PubMed: 28424165 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1090

PubMed: 29061961 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2103

PubMed: 29235459 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(9):2313-2324

PubMed: 27697994 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(7):E1072-E1080

PubMed: 28137841 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1892-1904

PubMed: 28108509 ( click the link to review the publication )

Oncogene, 2017, 36(26):3651-3660

PubMed: 28192408 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Front Immunol, 2017, 8:1221

PubMed: 29033940 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2586-2597

PubMed: 28835384 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1779-1790

PubMed: 28619753 ( click the link to review the publication )

J Antimicrob Chemother, 2017, 72(2):467-477

PubMed: 27999013 ( click the link to review the publication )

Int J Oncol, 2017,

PubMed: 28339079 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 85:149-158

PubMed: 28254430 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 91(Pt A):1-8

PubMed: 28834761 ( click the link to review the publication )

PLoS One, 2017, 12(3):e0172858

PubMed: 28257435 ( click the link to review the publication )

Am J Reprod Immunol, 2017, 78(4)

PubMed: 28635072 ( click the link to review the publication )

J Pharmacol Sci, 2017, 134(4):197-202

PubMed: 28779993 ( click the link to review the publication )
Anticancer Drugs, 2017, 28(4):436-445

PubMed: 28125433 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28418900 ( click the link to review the publication )

Oncotarget, 2017, 8(4):6102-6113

PubMed: 28008149 ( click the link to review the publication )

Oncotarget, 2017, 8(14):23213-23227

PubMed: 28390196 ( click the link to review the publication )

JCI Insight, 2017,

PubMed: 28422756 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29245981 ( click the link to review the publication )

Oncotarget, 2017, 8(70):114924-114934

PubMed: 29383130 ( click the link to review the publication )

Oncotarget, 2017, 8(47):81794-81802

PubMed: 29137222 ( click the link to review the publication )

Oncotarget, 2017, 8(1):742-756

PubMed: 27888629 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(6):E980-E989

PubMed: 28049849 ( click the link to review the publication )

Blood, 2016, 127(25):3192-201

PubMed: 27095788 ( click the link to review the publication )

Blood, 2016, 128(4):574-83

PubMed: 27235137 ( click the link to review the publication )

Ann Oncol, 2016, 27(6):1123-8

PubMed: 26961147 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2242

PubMed: 27297582 ( click the link to review the publication )

Leukemia, 2016, 30(1):74-85

PubMed: 26220042 ( click the link to review the publication )

Leukemia, 2016, 30(2):337-45

PubMed: 26338274 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35(1):78

PubMed: 27176481 ( click the link to review the publication )

Pain, 2016, 157(1):137-46

PubMed: 26313408 ( click the link to review the publication )

Cancer Sci, 2016,

PubMed: 27348272 ( click the link to review the publication )

J Immunol, 2016, 197(7):2918-29

PubMed: 27559048 ( click the link to review the publication )

J Virol, 2016, 90(14):6443-52

PubMed: 27147739 ( click the link to review the publication )

Acta Pharmacol Sin, 2016, 37(10):1281-1297

PubMed: 27569389 ( click the link to review the publication )

Int J Oncol, 2016, 48(1):253-60

PubMed: 26549638 ( click the link to review the publication )

Oncol Rep, 2016, 36(6):3643-3650

PubMed: 27748929 ( click the link to review the publication )
Br J Pharmacol, 2016, 173(18):2726-38

PubMed: 27352269 ( click the link to review the publication )

Oncotarget, 2016, 7(50):83424-83436

PubMed: 27825137 ( click the link to review the publication )

Oncotarget, 2016, 7(27):41031-41046

PubMed: 27127886 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27174919 ( click the link to review the publication )

Leukemia, 2016, 30(9):1963

PubMed: 27600169 ( click the link to review the publication )

Thromb Haemost, 2016, 115(6):1138-46

PubMed: 26818901 ( click the link to review the publication )

Oncotarget, 2016, 7(45):72608-72621

PubMed: 27579615 ( click the link to review the publication )

Blood, 2015, 126(11):1336-45

PubMed: 26162407 ( click the link to review the publication )

Blood, 2015, 10.1182/blood-2014-12-618470

PubMed: 25833959 ( click the link to review the publication )

Blood, 2015, 10.1182/blood-2014-11-610329

PubMed: 25957390 ( click the link to review the publication )

Nat Commun, 2015, 6:5937

PubMed: 25583025 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(52):E7230-8

PubMed: 26668357 ( click the link to review the publication )

Haematologica, 2015, 100(1):77-86

PubMed: 25344523 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1628-38

PubMed: 25623213 ( click the link to review the publication )

Cell Rep, 2015, 10.1016/j.celrep.2015.01.002

PubMed: 25660021 ( click the link to review the publication )

Haematologica, 2015,

PubMed: 25957396 ( click the link to review the publication )

Int J Cancer, 2015, 10.1002/ijc.29579

PubMed: 25912635 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1593

PubMed: 25590803 ( click the link to review the publication )

Stem Cells, 2015, 10.1002/stem.1986

PubMed: 25753288 ( click the link to review the publication )

J Leukoc Biol, 2015, 98(6):1091-105

PubMed: 26265781 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0137917

PubMed: 26360058 ( click the link to review the publication )

Anticancer Res, 2015, 35(5):2699-708

PubMed: 25964548 ( click the link to review the publication )

Cancer Biol Med, 2015, 12(4):401-8

PubMed: 26779377 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25999352 ( click the link to review the publication )
Blood, 2014, 123(2):239-50

PubMed: 24191150 ( click the link to review the publication )

Blood, 2014, 123(26):4120-31

PubMed: 24711662 ( click the link to review the publication )

J Clin Invest, 2014, 124(4):1794-809

PubMed: 24569456 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(6):1576-89

PubMed: 24634471 ( click the link to review the publication )

Cell Death Differ, 2014, 21(10):1535-45

PubMed: 24992930 ( click the link to review the publication )

Pain, 2014, 155(6):1150-60

PubMed: 24631588 ( click the link to review the publication )

Br J Haematol, 2014, 166(4):529-39

PubMed: 24766330 ( click the link to review the publication )

J Immunol, 2014, 192(5):2063-70

PubMed: 24470496 ( click the link to review the publication )

PLoS One, 2014, 9(6):e98818

PubMed: 24901342 ( click the link to review the publication )

Chem Biol, 2014, 21(8):955-66

PubMed: 25065531 ( click the link to review the publication )

Nature, 2014, 516(7530):254-8

PubMed: 25274307 ( click the link to review the publication )

Leukemia, 2013, 28(3):629-41

PubMed: 24263804 ( click the link to review the publication )

Leukemia, 2013, 27(10):2096-100

PubMed: 23545990 ( click the link to review the publication )

Leukemia, 2013, 27(10):2094-6

PubMed: 23900138 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e827

PubMed: 24091670 ( click the link to review the publication )

J Pharmacol Exp Ther, 2013, 347(3):669-80

PubMed: 24068833 ( click the link to review the publication )

Acta Pharmacol Sin, 2013, 34(9):1201-7

PubMed: 23892273 ( click the link to review the publication )

PLoS One, 2013, 8(2):e57809

PubMed: 23460911 ( click the link to review the publication )

PLoS One, 2013, 8(8):e69126

PubMed: 23936317 ( click the link to review the publication )

Leuk Res, 2013, 38(1):109-15

PubMed: 23981382 ( click the link to review the publication )

Blood, 2012, 120(19):3978-85

PubMed: 22927247 ( click the link to review the publication )

Am J Pathol, 2012, 180(5):1906-16

PubMed: 22433439 ( click the link to review the publication )

PLoS One, 2012, 7(7):e40852

PubMed: 22808277 ( click the link to review the publication )

Eur J Cancer, 2011, 48(1):149-57

PubMed: 22079609 ( click the link to review the publication )

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述

特性

Calistoga 暗示 CAL-101治疗血液恶性肿瘤可能有更广泛的应用价值。

靶点

p110δ ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)
2.5 nM	89 nM

体外研究

CAL-101 对p110α, p110β,和p110γ作用效果不大。CAL-101作用于原代嗜碱细胞特定阻断FcϵR1 p110δ调节的 CD63表达，EC50 为8 nM。与急性髓性白血病(AML) 和骨髓增生性肿瘤(MPN) 细胞相比，CAL-101 作用于B-cell急性淋巴细胞白血病(B-ALL)和慢性淋巴细胞白血病(CLL) 细胞时显示更强的活性。CAL-101 作用于SU-DHL-5, KARPAS-422 和CCRF-SB细胞，降低pAktS473, pAktT308, 和下游靶点S6， EC50为0.1到1.0 μM。 ^[1] CAL-101 作用于CLL细胞，诱导选择性细胞毒性，不是通过突变状态或间期细胞遗传学,主要通过caspase依赖机制。与正常B细胞相比，CAL-101作用于CLL 细胞优先产生细胞毒性，和LY294002相比，作用于其他造血细胞不会产生毒性。CAL-101 作用于T 细胞和天然杀伤细胞缺乏直接的细胞毒性潜能。CAL-101抑制炎症细胞因子的产生,比如 IL-6, IL-10, TNF-α,和IFN-γ,且激活诱导的细胞因子,如CD40L。CAL-101 也抗CD40L调节的CLL细胞存活。^[2] CAL-101 作用于L1236和L591细胞, 诱导细胞在G1期积累，在S期下降，说明 CAL-101可以作为治疗霍杰金淋巴瘤(HL)的一种新策略。^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MEC1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnPoSG1UVw>?	NEfZbVJKSzVyPUKwMlQh\|ryP	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl7OUO1Nkc,OjV7OUmzOVI9N2F-
CLL PBMCs	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWTwZVQ3TE2VTx?=	MlrUTWM2OD1{Lkmgcm0>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzN{K2O{c,OjV7MUeyOlc9N2F-
U266	M33ze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnyNVhsPDBizszN	M4jQVVQ5KGh?		MnLRO\|kvPSViaX7obYJqfGmxbjDyZZRm	MnrVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|M{mzN\|IoRjJ3M{O5N\|MzRC:jPh?=
K562	MYXGeY5kfGmxbjDBd5NigQ>?	NF\DflMyKM7:TR?=	MUSzJIg>		M1L6WmlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbh?=	NYDO[Yc2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNVQ4PzVpPkK1NFE1Pzd3PD;hQi=>
K562	NGPjeZRHfW6ldHnvckBCe3OjeR?=	MY[xJO69VQ>?	M2TzdlMhcA>?		M4\HcmlvcGmkaYTpc44hd2ZiUEewV\|ZMKHCqb4PwbI9zgWyjdHnvci=>	NXXrXm9rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNVQ4PzVpPkK1NFE1Pzd3PD;hQi=>
K562	M2DjbmZ2dmO2aX;uJGF{e2G7	MYqxJO69VQ>?	NHXSZ2M{KGh?		MoLPTY5pcWKrdHnvckBw\iCJU1uzJJBpd3OyaH;yfYxifGmxbh?=	NH\XdZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCxOFc4PSd-MkWwNVQ4PzV:L3G+
K562	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofvNUDPxE1?	MYS3NkBp		MWDJcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36=	M1TEVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEG0O\|c2Lz5{NUCxOFc4PTxxYU6=
Primary AML cell	NUTp[3F{TnWwY4Tpc44hSXO\|YYm=	M2Dy[lEh\|ryP	NHnDR\|c{KGh?		NUj2T4Z2UW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;u	NXvHc\|hWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNVQ4PzVpPkK1NFE1Pzd3PD;hQi=>
Primary AML cell	MVTGeY5kfGmxbjDBd5NigQ>?	NY\wWI9[OSEQvF2=	M{fST\|MhcA>?		MoDxTY5pcWKrdHnvckBw\iCSN{DTOmsheGixc4Doc5J6dGG2aX;u	M33YeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEG0O\|c2Lz5{NUCxOFc4PTxxYU6=
Primary AML cell	M17ZXmZ2dmO2aX;uJGF{e2G7	Ml7sNUDPxE1?	M1v5TVMhcA>?		NHfDNXdKdmirYnn0bY9vKG:oIFfTT\|MheGixc4Doc5J6dGG2aX;u	NFrEfYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCxOFc4PSd-MkWwNVQ4PzV:L3G+
Primary AML cell	NFfpUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\UNlEh\|ryP	NW\xT25GOyCq		MV3TeZBxemW\|c3nvckBw\iC{Ul7BJJN6dnSqZYPpdy=>	M{HRbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEG0O\|c2Lz5{NUCxOFc4PTxxYU6=
Microglia	M4rrR2Z2dmO2aX;uJGF{e2G7	MUO1JO69VQ>?	MUGxNEBp	NWTXZpdOTE2VTx?=	NEC0ZnNF\WO{ZXHz[UBw\iCWTl\hJJNm[3KndHnvckBnem:vIFzQV{1{fGmvdXzheIVlKCCyMUGw{tRFQTFyQT;EPVExSSCvaXPyc4dtcWF?	NXfiV5l7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NlU3QDRpPkK0OlI2Pjh2PD;hQi=>
Primary CLL cell	MYnGeY5kfGmxbjDBd5NigQ>?	MUGxJO69VQ>?	M33PXFE2KG2rbh?=	M4LPbWROW09?	MoDFRoxw[2u\|IFLDVk1qdmS3Y3XkJGxEWDFic3XybY5mNTViYXP0bZZifGmxbh?=	M1yyeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEC5NlM{Lz5{NECwPVI{OzxxYU6=
JEKO-1	MlzoSpVv[3Srb36gRZN{[Xl?	M1PiflEh\|ryP	NVHsU5R3PzJiaB?=		M37E[2lvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbjDpckBK\01vc4TpcZVt[XSnZDDKSWtQNTF?	NIexe3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O0NVU1OSd-MkOzOFE2PDF:L3G+
Granta-519	NWfSV\|JjTnWwY4Tpc44hSXO\|YYm=	M37oWFEh\|ryP	M4CybFIhcA>?		NV;WcmZsUW6qaXLpeIlwdiCxZjDBb5QpfDNyODmgdIhwe3Cqb4L5cIF1cW:w	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN2MUW0NUc,OjN\|NEG1OFE9N2F-
Granta-519	NFPnNppHfW6ldHnvckBCe3OjeR?=	M4KzNVEh\|ryP	MXWyJIg>		NH\iZ\|NKdmirYnn0bY9vKG:oIFHreEh{PDd\|KTDwbI9{eGixconsZZRqd25?	M3nONlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{SxOVQyLz5{M{O0NVU1OTxxYU6=
JEKO-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXe2V5Y3OTBizszN	NGjGWGY4OiCq		MlfyTY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;uJJNtcWeqdHz5	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN2MUW0NUc,OjN\|NEG1OFE9N2F-
JEKO-1	M1PDNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXqOUDPxE1?	NWfOepJPPzJiaB?=		MkfZ[I9meyCwb4SgbY5lfWOnIHPlcIwh[3mlbHWgZZJz\XO2IH;yJIFxd3C2b4Ppdy=>	NXzoVphpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2O\|YzOjBpPkKzOlc3OjJyPD;hQi=>
MAVER-1	NIKxVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPpbI82KM7:TR?=	NEjCWnA4OiCq		M{jufIRw\XNibn;0JIlv\HWlZTDj[YxtKGO7Y3zlJIFzemW\|dDDvdkBieG:ydH;zbZM>	NFzNWXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[3OlIzOCd-MkO2O\|YzOjB:L3G+
MINO	NIjuWmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUL6fI4yPSEQvF2=	NYTjdHVHPzJiaB?=		M1foXoRw\XNibn;0JIlv\HWlZTDj[YxtKGO7Y3zlJIFzemW\|dDDvdkBieG:ydH;zbZM>	NIm4c\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[3OlIzOCd-MkO2O\|YzOjB:L3G+
SP53	NUfqXndHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;s[pUxNjFizszN	MWm3NkBp		NILve2Zld2W\|IH7veEBqdmS3Y3WgZ4VtdCCleXPs[UBienKnc4Sgc5Ih[XCxcITvd4l{	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ5NkKyNEc,OjN4N{[yNlA9N2F-
HH	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;Rd3ZuOTBizszN	NEK0[nE4OiCq	NFLpcm1FVVOR	M3P6Vmlv\HWldHnvckBw\iCjcH;weI9{cXNic3zp[4h1dHl?	MnfUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MEG5OVkoRjJ{OECxPVU6RC:jPh?=
Myla	NVjJemEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU[xNEDPxE1?	MUG3NkBp	NG\DfmdFVVOR	MXHkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m\|	MlXmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MEG5OVkoRjJ{OECxPVU6RC:jPh?=
SR786	MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnvOI0yOCEQvF2=	M1HaXVczKGh?	NXLF[4xGTE2VTx?=	MkXo[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?=	NVS1NJhCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NFE6PTlpPkKyPFAyQTV7PD;hQi=>
HuT78	NI\KeppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XEcFExKM7:TR?=	NVHFfnJ[PzJiaB?=	NETmOpdFVVOR	Ml[z[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjhyMUm1PUc,OjJ6MEG5OVk9N2F-
MJ	NF;HU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWOxNEDPxE1?	MUG3NkBp	NIHER3hFVVOR	MXHkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m\|	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjhyMUm1PUc,OjJ6MEG5OVk9N2F-
DERL7	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHv6W3kyOCEQvF2=	M2Txc\|czKGh?	NHnzVlVFVVOR	NF;ZPXNld2W\|IH7veEBqdmS3Y3WgZZBweHSxc3nz	MkHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MEG5OVkoRjJ{OECxPVU6RC:jPh?=
L1236	MYnGeY5kfGmxbjDBd5NigQ>?	M1ntblExKM7:TR?=	MlnaNkBp		MVXJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25?	NXPsbHNWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVA5PzdpPkKyNlExQDd5PD;hQi=>
L428	NVjmPZN1TnWwY4Tpc44hSXO\|YYm=	MYWxNEDPxE1?	M324OFIhcA>?		M3y3fGlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbh?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMEi3O{c,OjJ{MUC4O\|c9N2F-
L591	MUTGeY5kfGmxbjDBd5NigQ>?	NWT6N251OTBizszN	MYWyJIg>		NV;wcpRrUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;u	MoHwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUC4O\|coRjJ{MkGwPFc4RC:jPh?=
KMH-2	M33SR2Z2dmO2aX;uJGF{e2G7	MUCxNEDPxE1?	NU\tSZRwOiCq		M{LQXmlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbh?=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMEi3O{c,OjJ{MUC4O\|c9N2F-
L1236	Ml3TSpVv[3Srb36gRZN{[Xl?	MYW1JO69VQ>?	MkHDNlQhcA>?		MUXCcI9kc3Nic3XjdoV1cW:wIH;mJJRp\SCFQ1y1	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMEi3O{c,OjJ{MUC4O\|c9N2F-
L591	MkDZSpVv[3Srb36gRZN{[Xl?	NVPJTpVYPSEQvF2=	MluyNlQhcA>?		MUDCcI9kc3Nic3XjdoV1cW:wIH;mJJRp\SCFQ1y1	Mn3MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUC4O\|coRjJ{MkGwPFc4RC:jPh?=
L1236	NFXMOJhCeG:ydH;zbZMhSXO\|YYm=	M1m3SlUh\|ryP	NGDBSZIzPCCq		NF3y[oVKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMEi3O{c,OjJ{MUC4O\|c9N2F-
L591	M{XteGFxd3C2b4Ppd{BCe3OjeR?=	M2Dxc\|Uh\|ryP	MViyOEBp		MXjJcoR2[3Srb36gc4Yh[XCxcITvd4l{	NEDQPFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNFg4Pyd-MkKyNVA5Pzd:L3G+
U-87MG	NVvQW4lMTnWwY4Tpc44hSXO\|YYm=	MlzMNVAxKG6P	NUXu[ItCOjRiaB?=	NH;PeHVFVVOR	Mm\XTY5pcWKrdHnvckBw\iBiY3XscEBucWe{YYTpc44>	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB5OU[wPUc,OjJyN{m2NFk9N2F-
SW1783	Mor3SpVv[3Srb36gRZN{[Xl?	NFXCNogyODBibl2=	NV7JXYxmOjRiaB?=	NIS0[mxFVVOR	M2rUO2lvcGmkaYTpc44hd2ZiIHPlcIwhdWmpcnH0bY9v	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB5OU[wPUc,OjJyN{m2NFk9N2F-
U-87MG	MoTZSpVv[3Srb36gRZN{[Xl?	NW\acnhuPSEQvF2=	MVSyOEBp	MUTEUXNQ	MlrvTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIIP1ZpN1[W62aXHscJk>	NHHr[W89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC3PVYxQSd-MkKwO\|k3ODl:L3G+
SW1783	MXrGeY5kfGmxbjDBd5NigQ>?	NXnuWpF5PSEQvF2=	MVqyOEBp	NUjTVpRRTE2VTx?=	Ml[5TY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIIP1ZpN1[W62aXHscJk>	NISzRpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC3PVYxQSd-MkKwO\|k3ODl:L3G+
U-373MG	MlzwSpVv[3Srb36gRZN{[Xl?	M{n0OVUh\|ryP	NEjxVoQzPCCq	M1rUOWROW09?	Mkj1TY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIIP1ZpN1[W62aXHscJk>	NYHuVnFpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwO\|k3ODlpPkKyNFc6PjB7PD;hQi=>
SK-MG3	MnyzSpVv[3Srb36gRZN{[Xl?	Moi3OUDPxE1?	M2fkSVI1KGh?	Mn:2SG1UVw>?	M4e3UWlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbjDzeYJ{fGGwdHnhcIx6	M2D5dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEe5OlA6Lz5{MkC3PVYxQTxxYU6=
SU-DHL-5	MmTPSpVv[3Srb36gRZN{[Xl?	NFHXVIcyKM7:TR?=	M4ezW\|I1KGh?	NWLXNpY4TE2VTx?=	NWHzfHVJUW6mdXP0bY9vKG:oIHHwc5B1d3Orcx?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODl3OU[wOkc,OjB7NUm2NFY9N2F-
WSU-NHL	MX\GeY5kfGmxbjDBd5NigQ>?	M4TaTVEh\|ryP	NIjKVZkzPCCq	M{T5fWROW09?	NXnZN3RsUW6mdXP0bY9vKG:oIHHwc5B1d3Orcx?=	MnHWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB7NUm2NFYoRjJyOUW5OlA3RC:jPh?=
CCRF-SB	NWX3bZFKTnWwY4Tpc44hSXO\|YYm=	NVfZWmNGOSEQvF2=	Mn;kNlQhcA>?	NVXaeoJ3TE2VTx?=	NXS4OWxzUW6mdXP0bY9vKG:oIHHwc5B1d3Orcx?=	NYrPelFzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC5OVk3ODZpPkKwPVU6PjB4PD;hQi=>
INA-6	NFHs[nZHfW6ldHnvckBCe3OjeR?=	MnzGOUDPxE1?	NVPkSJh3PiCq		MlT6TY5pcWKrdHnvckBw\iCSSUPLM2FsfCCjbnSgSXJMKHCjdHj3ZZk>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODVyNUG1PEc,OjB3MEWxOVg9N2F-
LB	NIPYZWVHfW6ldHnvckBCe3OjeR?=	MVu1JO69VQ>?	M{PkNFYhcA>?		M1HrcGlvcGmkaYTpc44hd2ZiUFm0T{9Cc3RiYX7kJGVTUyCyYYToe4F6	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODVyNUG1PEc,OjB3MEWxOVg9N2F-
B-cells	M4niWmZ2dmO2aX;uJIF{e2G7				M{XSUWlvcGmkaYTpc44hd2ZiUFmzT4RmdHSjIHnuJGIu[2WubIOgZpkheHKxbHnm[ZJifGmxbjDhd5NigSxiSVO1NEA:KDBwMEC2NUDPxE1w	M3jEd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUK0Olg5Lz5{MkmyOFY5QDxxYU6=
MOLM14	M2XpXmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MmDMN{Bl[Xm\|		NWLrTm1RSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xOOTRiY3XscJMh[W[2ZYKgN{Bl[Xm\|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEmFNUCgQUA{NjZizszNMi=>	MkL5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5N{SxNlcoRjJ5N{e0NVI4RC:jPh?=
MV4-11	NFq0S2tCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MlO5N{Bl[Xm\|		MUHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2YND2xNUBk\WyuczDh[pRmeiB\|IHThfZMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OCB;IE[uN{DPxE1w	NE\tflM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e3OFEzPyd-Mke3O\|QyOjd:L3G+
Jurkat	MlX6RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M{PuSFMh\GG7cx?=		NHrjbWpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFr1dotifCClZXzsd{Bi\nSncjCzJIRigXNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3MDC9JFcvQSEQvF2u	NXu3UXZvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O\|QyOjdpPkK3O\|c1OTJ5PD;hQi=>
Loucy	NFnLO4NCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NEnEZoY{KGSjeYO=		M4LjfWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTH;1Z5kh[2WubIOgZYZ1\XJiMzDkZZl{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGlEPTBiPTC4MlQh\|ryPLh?=	NXO2T2d[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O\|QyOjdpPkK3O\|c1OTJ5PD;hQi=>
MOLT4	NXrFRoc{SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MkniN{Bl[Xm\|		NEXvRpJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUHQ1KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBKSzVyIE2gNVAvPiEQvF2u	NYj3doJHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O\|QyOjdpPkK3O\|c1OTJ5PD;hQi=>
insect cells	MnfjSpVv[3Srb36gZZN{[Xl?				NETJWHdKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIH\1cIwhdGWwZ4ToJGhqey22YXfn[YQhWEl\|S3fhcY1iKGW6cILld5Nm\CCrbjDpcpNm[3RiY3XscJMtKEmFNUCgQUAxNjB6OTFOwG0v	MmDnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6NE[0OVEoRjJ5OES2OFUyRC:jPh?=
SUDHL6	NETOXIJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MkjwO\|IhcHK\|		M2HPRWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2XETGw3KGOnbHzzJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IECuNVE4PiEQvF2u	MnHYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6NE[0OVEoRjJ5OES2OFUyRC:jPh?=
insect cells	NFTse4JHfW6ldHnvckBie3OjeR?=				M1n3TGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigTIl{NXSjZ3fl[EBRUTONYnX0ZUBmgHC{ZYPz[YQhcW5iaX7z[YN1KGOnbHzzMEBKSzVyIE2gNE42PjVizszNMi=>	M1vCcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OES2OFUyLz5{N{i0OlQ2OTxxYU6=
SU-DHL4	MXzBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MnHIO\|IhcHK\|		MlHyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVVT3ETGw1KGOnbHzzJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IEGuOkDPxE1w	NX;lVHg4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4OFY1PTFpPkK3PFQ3PDVzPD;hQi=>
Pfeiffer	M2PSUWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M4jRSVczKGi{cx?=		NXPLbFE{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQ[oVq\m[ncjDj[YxteyCvZXHzeZJm\CCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUCgQUA3NjhizszNMi=>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzh2NkS1NUc,Ojd6NE[0OVE9N2F-
KARPAS422	MYXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NIewUG04OiCqcoO=		MkTNRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCNQWLQRXM1OjJiY3XscJMhdWWjc4Xy[YQh[W[2ZYKgO\|IhcHK\|IHL5JIFt[W2jcjDicJVmKGG\|c3H5MEBKSzVyIE2gPE4yKM7:TT6=	MmnIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6NE[0OVEoRjJ5OES2OFUyRC:jPh?=
Sf21	NWLnPY5QTnWwY4Tpc44h[XO\|YYm=		NEjQRW8{OCCvaX7z		MlP4TY5pcWKrdHnvckBw\iCQLYTldo1qdmGuIFjpd\|YufGGpZ3XkJJJm[2:vYnnuZY51KG[3bHytcIVv\3SqIHj1cYFvKFCLM1ugdFEyOGKndHGveY51[WepZXSgdoVkd22kaX7hcpQh\nWubDDs[Y5ofGhiaIXtZY4heDh3YXzwbIEh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJHNnOjFiaX7z[YN1KGOnbHzzJJV{cW6pIGDJVFIwSVSSIHHzJJN2[nO2cnH0[UBi\nSncjCzNEBucW6\|IHL5JHRTNU[URWSgZZN{[XluIFnDOVAhRSB\|Lkeg{txONg>?	Mnj3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzME[5PVEoRjJ6MUC2PVkyRC:jPh?=
Sf21	M3vQO2Z2dmO2aX;uJIF{e2G7		M4\XeFMxKG2rboO=		NIH6VoNKdmirYnn0bY9vKG:oIF6teIVzdWmwYXygTIl{Pi22YXfn[YQhemWlb33ibY5idnRiZoXscE1t\W6pdHigbJVu[W5iUFmzT{BxOTFyYnX0ZU92dnSjZ3fl[EBz\WOxbXLpcoFvfCCodXzsJIxmdme2aDDoeY1idiCyOEXhcJBp[SCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z{MTDpcpNm[3RiY3XscJMhfXOrbnegVGlROi:DVGCgZZMhe3Wkc4TyZZRmKGGodHXyJFMxKG2rboOgZpkhXFJvRmLFWEBie3OjeTygTWM2OCB;IEOuO{DPxE1w	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDFyNkm5NUc,OjhzME[5PVE9N2F-
RPMI8266	NYDPRm9RSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NEHLVXo4OiCqcoO=		MlzKRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCUUF3JPFI3PiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4xODV2OTFOwG0v	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN{NU[wNUc,Ojh\|MkW2NFE9N2F-
Raji	MmTMRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NXXsV4x{PzJiaILz		MlXMRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCUYXrpJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkCwPVk2KM7:TT6=	M4fLWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{K1OlAyLz5{OEOyOVYxOTxxYU6=
KARPAS422	NEL2WG1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=				M3L0Tmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGtCWlCDU{SyNkBk\WyuczDifUBES0t6IHHzd4F6NCCJSUWwJF0hOC54ODFOwG0v	MkL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6M{W4NFUoRjJ6OEO1PFA2RC:jPh?=
Pfeiffer	NX7rUpoyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NGjZXWVIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBR\mWrZn\ldkBk\WyuczDifUBES0t6IHHzd4F6NCCJSUWwJF0hOC55NDFOwG0v	NVjXdYM5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4N\|U5ODVpPkK4PFM2QDB3PD;hQi=>
Saos-2	M1zZepFJXFNiYYPzZZk>				NGnSdVZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz	NWLpeXZ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	NGjXVWVyUFSVIHHzd4F6				NWfMVXpleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MG 63 (6-TG R)	M3vWVJFJXFNiYYPzZZk>				NW\5ZVZLeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	NFS0WmRyUFSVIHHzd4F6				NYfnSlFGeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	Mm\EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	NXrOZ5JYeUiWUzDhd5NigQ>?				MVnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	M{XpPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	MmPXdWhVWyCjc4PhfS=>				M121TJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy\|	NUPJUGhpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	M325UZFJXFNiYYPzZZk>				MVfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	MlnNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1	M2rNdZFJXFNiYYPzZZk>				MkjrdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
LAN-5	NEnWNHZyUFSVIHHzd4F6				MoXrdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy\|	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SUDHL6	NVXHVXdGSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M4qzO\|czKGi{cx?=		NXzpW2VxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTWWRJVDZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNEUzhiYYPzZZktKEmFNUCgQUAxNjZ3IN88UU4>	M3XmVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUO0PVM3Lz5{OUWzOFk{PjxxYU6=
RPMI8226	MUnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MlrmO\|IhcHK\|		MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFKSTVm4NlI3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC1MlQ6KM7:TT6=	M{W2dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUO0PVM3Lz5{OUWzOFk{PjxxYU6=
Raji	NU\2UIVmSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NI\vUoY4OiCqcoO=		Mn;5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCUYXrpJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB7Lkm1JO69VS5?	NInqNVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzOFk{Pid-Mkm1N\|Q6OzZ:L3G+
SU-DHL6	MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				M1vvfGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNWNUSKTE[gZ4VtdHNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvODR{IN88UU4>	NXfzbYJYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2NFE6QTFpPkK5OlAyQTlzPD;hQi=>
MOLM13	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1zRSFczKGi{cx?=		NGrrTYxIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOV0yPMUOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gcJVucW6nc3PlcpQh[XO\|YYmsJGdKPTBiPTCxMlch\|ryPLh?=	NWi5cJBxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwOVM4OjFpPkOwNFU{PzJzPD;hQi=>
MOLM14	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1uwd\|czKGi{cx?=		MXLHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNU2xOOTRiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9ibIXtbY5me2OnboSgZZN{[XluIFfJOVAhRSB4LkSg{txONg>?	MljWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNUO3NlEoRjNyMEWzO\|IyRC:jPh?=
MOLM14	NWLncJlvSW62aYT1cY9zKGG\|c3H5	M3j0SFExOCCvZz;r[y=>	NWfSR5FYOTRiZHH5dy=>		MUPBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPT1zNNVQh[2WubIOgfIVvd2e{YX\0[YQhcW5iboWvcpUhdW:3c3WgZZN{\XO\|ZXSgZZMhfHWvb4Kg[5Jwf3SqIHnubIljcXSrb36gZZQhOTByIH3nM4toNCCybzDh[I1qdmm\|dHXy[YQh\GGrbImgeoliKGejdnHn[UBld3OnZDDmc5IhOTRiZHH5d{BidmRibXXhd5Vz\WRiZHHpcJkh\HW{aX7nJINwdXCxdX7kJIRwe2mwZzDy[YxifGm4ZTD0c{Bkd262cn;s	NESye\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC1N\|czOSd-M{CwOVM4OjF:L3G+
MOLM14	MWDBcpRqfHWvb4KgZZN{[Xl?	MljENVAxKG2pL3vn	MUixOEBl[Xm\|		M3e4SWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yPCClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDueU9vfSCvb4Xz[UBie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gZZBweHSxc3nzJIF1KDFyMDDt[{9s\yxicH:gZYRucW6rc4TldoVlKGSjaXz5JJZq[SCpYY\h[4Uh\G:\|ZXSg[o9zKDF2IHThfZMh[W6mIH3lZZN2emWmIHThbYx6KGS3cnnu[{Bkd22yb4Xu[EBld3OrbnegZpkhXFWQRVygZoF{\WRiYYPzZZk>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB3M{eyNUc,OzByNUO3NlE9N2F-
MOLM14	MmnCRY51cXS3bX;yJIF{e2G7	Mn\pNVAxKG2pL3vn	M2DrfFE1KGSjeYO=		MnToRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MUVE1KGOnbHzzJJhmdm:pcnHmeIVlKGmwIH71M452KG2xdYPlJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geJVud3JicILvcIln\XKjdHnvckAyODBibXevb4ctKHCxIHHkcYlvcXO2ZYLl[EBl[WmueTD2bYEh\2G4YXflJIRwe2WmIH\vdkAyPCCmYYnzJIFv\CCvZXHzeZJm\CCmYXnsfUBlfXKrbnegZ49ueG:3bnSg[I9{cW6pIHL5JGtqNTZ5IHzhZoVtdGmwZzDiZZNm\CCrbX31co9p	M124U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEWzO\|IyLz5\|MEC1N\|czOTxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	PUMA / p53 ; PubMed: 28008149 Oncotarget Parental and p53-KD HCT116 cells were treated with 10 μmol/L idelalisib for 24 hours. PUMA expression was analyzed by Western blotting. Bim / Bcl-xl / Bid / Mcl-1; PubMed: 28008149 Oncotarget HCT116 cells treated with 10 μmol/L idelalisib at indicated time point. The expression of indicated Bcl-2 family members was analyzed by Western blotting. p-p65; PubMed: 28008149 Oncotarget HCT116 cells were treated with 10 μmol/L idelalisib at indicated time point. p-p65 (S536) and p65 expression was analyzed by Western blotting. p-AKT / AKT; PubMed: 28008149 Oncotarget HCT116 cells were treated with 10 μmol/L idelalisib at indicated time point. Total AKT and p-AKT expression was analyzed Western blotting. Cleaved caspase 3 / Cleaved caspase 9; PubMed: 28008149 Oncotarget HepG2 cells were treated with 5μmol/L idelalisib at indicated time point. Cleaved-caspase 3 and 9 were analyzed by western blotting. Mcl-1 / Bcl-2 / Bid / Bcl-xl / Noxa / Bak / Bax ; PubMed: 30224718 Cell Death Dis HepG2 cells were treated with 5 μmol/L idelalisib at indicated time points. The expression of indicated Bcl-2 family members was analyzed by western blotting and normalized to β-actin. The data represent the mean ± SD of three independent experiments. P < 0.01 (one-way ANOVA with Tukey’s post hoc test). p-FoxO3a / FoxO3a; PubMed: 30224718 Cell Death Dis HepG2 cells were treated with 5 μmol/L idelalisib for 24 h. Indicated protein expression was analyzed by western blotting and p-FoxO3a normalized to FoxO3a, p-AKT normalized to AKT. The data represent the mean ± SD of three independent experiments. P < 0.01 (one-way ANOVA with Tukey’s post hoc test). Akt(T308) / PDK1(S241) / GSK-3β(S9); PubMed: 27342398 Clin Cancer Res JeKo-1, Mino, and Granta 519 cells or cells from four different MCL patients were serum-starved for 1h and then treated with DMSO, or with 0.5, 1, or 3μM for 1h; the cells were then co-cultured with IgM (10ng/μL) for 15min before harvesting. Cell extracts were prepared, and 30μg (cell lines) or 50μg (primary cells) protein was loaded for immunoblot analyses. The effects of idelalisib on Akt (Thr308) and total Akt, PDK1 (Ser241) and total PDK1, GS3K-3β (Ser9) and total GSK-3β protein expression levels were detected in (A) JeKo-1, Mino and Granta 519 cells.	28008149 30224718 27342398
Growth inhibition assay	Cell viability; PubMed: 28008149 Oncotarget Indicated cell lines were treated with different concentrations of idelalisib for 72 hours. Cell proliferation was determined by MTS assay. Results were expressed as means ± SD of three independent experiments. Cell viability; PubMed: 30224718 Cell Death Dis The indicated cell lines were treated with increasing concentrations of idelalisib for 72 h. Cell viability was determined by MTS assay.	28008149 30224718

激酶实验：^[2]	- 合并 PI3K实验: 用全CLL和正常B细胞溶解物进行PI3K实验。进行PI3K ELISA 实验。全细胞抽提物加到PI(4,5)P2 底物和反应 buffer（包含 ATP)的混合物中，在室温下温育。加入 PI(3,4,5)P3 探测器和 EDTA混合，反应终止，在室温下温育1小时。混合物转移到PI3K ELISA板上，再温育1小时。冲洗反应板，然后和第二探测器再温育30分钟。再次冲洗反应板, 加入3,3′,5,5′-四甲基联苯胺溶液，反应5分钟，加入H₂SO₄ 终止反应。在450纳米处读数。
细胞实验：^[2]	- 合并 Cell lines: CLL B 细胞或健康志愿者的T细胞或NK细胞 Concentrations: 0.01-100 μM Incubation Time: 48小时 Method: 进行MTT实验测定细胞毒性。1×10⁵个细胞和CAL-101一起温育。加入MTT试剂, 再次温育20小时，然后用溶于PBS的硫酸鱼精蛋白冲洗。加入DMSO, 用分光光度计在540纳米处测定吸光度。使用膜联蛋白/PI液式细胞计检查在不同时间点测定细胞存活力，分析数据。每个样本至少计数10⁴个细胞。以全部阳性细胞与未处理细胞之比百分数的形式来表示实验结果。加入100 μM Z-VAD检测caspase-依赖的细胞凋亡。加入 1 μg/mL CD40L, 800 U/mL IL-4, 50 ng/mL BAFF, 20 ng/mL TNF-α测定存活信号, 或者共培养在纤连蛋白或 HS-5 细胞系基质包被的板上。基质共培养在75cm²培养瓶 (80%-100% 融合率) 培养24 小时，然后加入CLL细胞。 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	83 mg/mL warmed (199.79 mM)
	Ethanol	23 mg/mL (55.36 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 2% DMSO+20%PEG 300+ddH2O	5mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Idelalisib (CAL-101, GS-1101) SDF

分子量	415.42
化学式	C₂₂H₁₈FN₇O
CAS号	870281-82-6
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03582098	Completed	Drug: Idelalisib\|Drug: Rituximab	Chronic Lymphocytic Leukaemia	Gilead Sciences	September 12 2018	--
NCT03151057	Active not recruiting	Drug: Idelalisib 100 MG\|Drug: Placebo Oral Tablet	B Cells-Tumors\|B Cell Chronic Lymphocytic Leukemia\|Follicular Lymphoma\|Mantle Cell Lymphoma\|Large B-Cell Diffuse Lymphoma of Bone (Diagnosis)	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Gilead Sciences	July 31 2018	Phase 1
NCT03568929	Recruiting	Drug: Idelalisib	Follicular Non-Hodgkin''s Lymphoma Refractory	Gilead Sciences	May 25 2018	--

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
What is the recommended dose of CAL-101 and the route of administration for mouse studies?
回答：
According to the following paper, S2226 can be used by I.V. administration at the concentration of 40 mg/kg. https://www.ncbi.nlm.nih.gov/pubmed/24625684

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

泛PI3K抑制剂

LY294002 : Pan-PI3Kα/δ/β inhibitor, IC50=0.5 μM/0.57 μM/0.97 μM.
活性最高的PI3K抑制剂

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
用于临床的PI3K抑制剂

Hexestrol : Phase II for Advanced Breast Cancer.
最新的PI3K抑制剂

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

研究领域

产品类型

定制您的化合物库

Idelalisib (CAL-101, GS-1101)

客户使用Selleck生产的Idelalisib (CAL-101, GS-1101)发表文献192篇：

产品安全说明书

PI3K抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Idelalisib (CAL-101, GS-1101) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-01-06)

技术支持

常见问题及建议解决方法

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品